ATE524195T1 - Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen - Google Patents

Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen

Info

Publication number
ATE524195T1
ATE524195T1 AT02726561T AT02726561T ATE524195T1 AT E524195 T1 ATE524195 T1 AT E524195T1 AT 02726561 T AT02726561 T AT 02726561T AT 02726561 T AT02726561 T AT 02726561T AT E524195 T1 ATE524195 T1 AT E524195T1
Authority
AT
Austria
Prior art keywords
protein
clfa
monoclonal antibodies
treatment
infections
Prior art date
Application number
AT02726561T
Other languages
English (en)
Inventor
Joseph M Patti
Jeff T Hutchins
Paul Domanski
Pratisksha Patel
Andrea Hall
Original Assignee
Inhibitex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc filed Critical Inhibitex Inc
Application granted granted Critical
Publication of ATE524195T1 publication Critical patent/ATE524195T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02726561T 2001-01-26 2002-01-28 Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen ATE524195T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26407201P 2001-01-26 2001-01-26
US27461101P 2001-03-12 2001-03-12
US29841301P 2001-06-18 2001-06-18
US30811601P 2001-07-30 2001-07-30
PCT/US2002/002296 WO2002072600A2 (en) 2001-01-26 2002-01-28 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections

Publications (1)

Publication Number Publication Date
ATE524195T1 true ATE524195T1 (de) 2011-09-15

Family

ID=27500806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726561T ATE524195T1 (de) 2001-01-26 2002-01-28 Monoklonale antikörper gegen das clfa-protein und verfahren zur verwendung bei der behandlung bzw. pr vention von infektionen

Country Status (15)

Country Link
US (2) US6979446B2 (de)
EP (1) EP1377314B1 (de)
JP (1) JP4171816B2 (de)
KR (2) KR20030071861A (de)
CN (2) CN1489474A (de)
AT (1) ATE524195T1 (de)
AU (1) AU2002256985B8 (de)
BR (1) BR0207068A (de)
CA (1) CA2434762A1 (de)
DK (1) DK1377314T3 (de)
ES (1) ES2372686T3 (de)
IL (2) IL157041A0 (de)
MX (1) MXPA03006651A (de)
PT (1) PT1377314E (de)
WO (1) WO2002072600A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994855B1 (en) * 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
HUE026914T2 (en) 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2006138627A2 (en) * 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
AU2007210170A1 (en) * 2006-01-27 2007-08-09 Merck Sharp & Dohme Corp. Antigen-binding proteins targeting S. aureus ORF0657n
WO2007100580A2 (en) * 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
WO2008136861A2 (en) * 2006-11-22 2008-11-13 3M Innovative Properties Company Inactivated and dried biological preparations
US20100099115A1 (en) 2006-11-22 2010-04-22 Mach Patrick A Systems and methods for preparing and analyzing samples
US20100129837A1 (en) * 2006-11-22 2010-05-27 Mach Patrick A Methods of capturing bacterial whole cells and methods of analyzing samples for bacteria
WO2008131063A1 (en) * 2007-04-19 2008-10-30 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
CN101663581A (zh) * 2007-04-19 2010-03-03 3M创新有限公司 水分散性二氧化硅纳米颗粒在连接生物分子方面的用途
EP2164869A2 (de) * 2007-05-31 2010-03-24 Merck Sharp & Dohme Corp. Auf s. aureus orf0657n abzielende antigenbindende proteine
EP2220500A4 (de) * 2007-11-20 2010-12-15 3M Innovative Properties Co Verfahren zur analyse einer probe für ein bakterium unter verwendung eines diacetylenhaltigen polymersensors
JP2011516824A (ja) * 2008-02-20 2011-05-26 スリーエム イノベイティブ プロパティズ カンパニー 全細胞捕捉及びａｔｐ分析を用いた細菌試料の分析方法
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
TR201809128T4 (tr) 2009-07-15 2018-07-23 Aimm Therapeutics Bv Gram-pozitif bakterilere spesifik bağlanan bileşikler.
AU2010291835A1 (en) * 2009-09-03 2012-04-19 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
MX366890B (es) * 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
US8324352B2 (en) 2009-12-07 2012-12-04 Decimmune Therapeutics, Inc. Anti-inflammatory antibodies and uses therefor
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
KR101044438B1 (ko) * 2011-03-29 2011-06-27 최희선 저수탱크
US20140271649A1 (en) * 2011-07-15 2014-09-18 The University Of Chicago Methods and compositions for inhibiting staphylococcus agglutination in blood
JP2014534169A (ja) * 2011-09-23 2014-12-18 ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓエピトープ結合部位を形成するペプチドまたはペプチドの配置
US8834898B2 (en) * 2011-12-16 2014-09-16 Boise State University Cholera toxin chimera and its use as a staph vaccine
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944B1 (de) * 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobuline und varianten gegen pathogene mikroben
CA2871614C (en) 2012-04-27 2021-08-31 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
EP2705852A1 (de) * 2012-09-06 2014-03-12 Université de Lausanne Immunogene Zusammensetzung gegen Staphylococcus aureus, umfassend ein inaktiviertes rekombinantes nicht pathogenes Bakterium
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
US9409977B2 (en) 2013-03-12 2016-08-09 Decimmune Therapeutics, Inc. Humanized, anti-N2 antibodies
CA2920147C (en) 2013-08-07 2022-09-20 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
US11446371B2 (en) * 2015-11-05 2022-09-20 The Texas A&M University System Targeting of ligand binding sites in ClfA
AU2017214733B2 (en) 2016-02-04 2022-09-29 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
KR20190005998A (ko) 2016-05-18 2019-01-16 젠맵 비. 브이 항체 및 감염성 질환의 치료에서의 그의 사용 방법
EP3672635A4 (de) * 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania Monoklonale antikörper gegen pathologisches alpha-synuclein und verfahren zur verwendung davon
EP3784776A4 (de) * 2018-05-23 2022-01-26 National University of Singapore Blockade der cd2-oebrflächenexpression und expression chimärer antigenrezeptoren für die immuntherapie von t-zell-malignomen
CN110632298B (zh) * 2018-06-25 2023-04-18 洛阳普泰生物技术有限公司 犬腺病毒1型单克隆抗体、可变区序列、杂交瘤细胞株及其应用
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
MA54945A (fr) 2019-02-12 2021-12-22 Regeneron Pharma Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
KR20240167591A (ko) * 2023-05-18 2024-11-27 한국과학기술연구원 항-엔도글린 항체 및 이의 용도
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
CN118406141B (zh) * 2024-04-25 2024-11-22 中国人民解放军总医院第四医学中心 一种抗金黄葡萄球菌胞外黏着蛋白的纳米抗体及其衍生产品和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK219084D0 (da) 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
US5240833A (en) * 1989-01-30 1993-08-31 The Biomembrane Institute Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5256542A (en) * 1992-03-09 1993-10-26 Tanox Biosystems, Inc. Selecting low frequency antigen-specific single B lymphocytes with correction for background noise
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
CA2153661A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
EP0749321B1 (de) * 1994-02-09 2007-01-24 Epitopix LLC Aktive immunisierung gegen ein siderophores rezeptorprotein
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
EP0781847A1 (de) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanisierter monoklonaler Antikörper
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
SE9704141D0 (sv) 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ES2270638T3 (es) 1998-10-29 2007-04-01 Dakocytomation Denmark A/S Deteccion de microorganismos acido-resistentes en las heces.
WO2000064925A1 (en) 1999-04-28 2000-11-02 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Method of inhibiting leukocyte adhesion to fibrinogen

Also Published As

Publication number Publication date
JP4171816B2 (ja) 2008-10-29
US20050287164A1 (en) 2005-12-29
ES2372686T3 (es) 2012-01-25
MXPA03006651A (es) 2004-11-12
KR20030071861A (ko) 2003-09-06
US6979446B2 (en) 2005-12-27
CA2434762A1 (en) 2002-09-19
IL157041A (en) 2010-05-31
US20030099656A1 (en) 2003-05-29
US7364738B2 (en) 2008-04-29
JP2004534000A (ja) 2004-11-11
KR20090039851A (ko) 2009-04-22
CN101928343A (zh) 2010-12-29
EP1377314A4 (de) 2005-05-11
CN101928343B (zh) 2014-09-17
BR0207068A (pt) 2004-12-21
CN1489474A (zh) 2004-04-14
EP1377314B1 (de) 2011-09-14
AU2002256985B2 (en) 2007-10-11
AU2002256985B8 (en) 2008-03-20
DK1377314T3 (da) 2011-12-12
KR101015496B1 (ko) 2011-02-22
PT1377314E (pt) 2012-01-02
EP1377314A2 (de) 2004-01-07
IL157041A0 (en) 2004-02-08
WO2002072600A3 (en) 2003-11-06
WO2002072600A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
IL157041A0 (en) Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DE69940404D1 (de) Multikomponenten Impfstoffe gegen Staphylococcus aureus
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE427116T1 (de) Behandlung von bakteriellen infektionen
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE227306T1 (de) Thrombin-inhibitoren als anticoagulierende mittel
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
DE60134881D1 (de) Monoklonale antikörper gegen das map-protein und verfahren zu dessen anwendung bei der behandlung bzw. prävention von infektionen
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
DE602004006287D1 (de) Korrosionsschutzmittel zur oberflächlichen behandlung von gläsernem spülgut
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377314

Country of ref document: EP